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Background: This study was performed to investigate the effect of microRNA-203 (miR-203) on cell proliferation
and migration in triple-negative breast cancer (TNBC).
Methods: Real-time PCR was performed to detect the expression of miR-203 in TNBC cell lines. miR-203 precursor
and control microRNA (miRNA) were transfected into triple-negative breast cancer (TNBC) cell lines and the effects
of miR-203 up-regulation on the proliferation and migration of cells were investigated. Meanwhile, the mRNA and
protein levels of baculoviral IAP repeat-containing protein 5 (BIRC5) and Lim and SH3 domain protein 1 (LASP1)
were measured. Luciferase assays were also performed to validate BIRC5 and LASP1 as miR-203 targets.
Results: Both miR-203 and BIRC5 siRNA signicantly inhibited cell proliferation in TNBC cells. Both miR-203 and
LASP1 siRNA signicantly inhibited cell migration in TNBC cells, also. Moreover, up-regulated of BIRC5 and LASP1 was
able to abrogate the effects induced by transfection with the miR-203 precursor.
Conclusions: These data suggest that miR-203 may function as a tumor suppressor in TNBC cells. Thus, miR-203
could be a potential therapeutic target for this disease.
Keywords: Triple-negative breast cancer, MiR-203, baculoviral IAP repeat-containing protein 5, Lim and SH3 domain
protein 1, Proliferation, MigrationBackground
Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death in women world-
wide, accounting for 23% (1.38 million) of all new cancer
cases and 14% (458,400) of all cancer deaths in 2008.
Approximately half of all breast cancer cases and 60% of
breast cancer-related deaths are estimated to occur in
developing countries [1]. The large number of etiological
factors and the complexity of breast cancer present chal-
lenge for prevention and treatment.
Triple-negative breast cancer (TNBC) is defined histolo-
gically as invasive carcinoma of the breast that lacks stain-
ing for estrogen receptor (ER), progesterone receptor
(PgR), and the human epidermal growth factor receptor-2
(HER2). TNBC is associated with high proliferative rates,* Correspondence: shiyur01@163.com
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reproduction in any medium, provided the orearly recurrence, and poor survival rates. Much effort has
been spent on the study of the biological behavior of
TNBC cells to develop effective treatment strategies.
MicroRNAs (miRNAs) are small, non-coding RNAs of
19–25 nucleotides in length that are endogenously
expressed in mammalian cells. miRNAs regulate gene
expression post-transcriptionally, by pairing with com-
plementary nucleotide sequences in the 3’-UTRs of spe-
cific target mRNAs [2,3]. This recently identified type of
gene regulators is involved in modulating multiple cellu-
lar pathways, including cell proliferation, differentiation,
and migration. Thus, miRNAs may function as onco-
genic miRNAs or tumor suppressors [4-6]. Over 50% of
miRNA genes are located in cancer-associated genomic
regions [7]. The deletion or epigenetic silencing of a
miRNA that normally represses the expression of one or
more oncogenes might lead to carcinogenesis, tumor
growth and invasion, as has been demonstrated for miR-
200, miR-122 and miR-203 [8-10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cers, including hepatocellular carcinoma [11], colon can-
cer [12], prostate cancer [13], and laryngeal cancer [14].
Because the down-regulated of miR-203 is common to a
number of cancers, it has been hypothesized that miR-
203 may play an important role in tumorigenesis and
tumor development. However, the function of miR-203
in breast cancer remains unclear, especially in TNBC.
In this paper, we showed that miR-203 was down-
regulated in TNBC cell lines and that the ectopic over-
expression of miR-203 blocked tumor cell proliferation
and migration in vitro. Furthermore, BIRC5 and LASP1
were identified as two direct functional targets of miR-
203 in TNBC cells. These data suggest that the reduced
expression of miR-203 facilitates the development and
metastasis of TNBC.
Materials and methods
Cell culture and treatment
Human triple-negative breast cancer cell lines (MDA-
MB-468 and MDA-MB-231) and normal breast cell line
MCF-10A, were purchased from the American Type
Culture Collection. MDA-MB-468 and MDA-MB-231
cells were maintained in DMEM (Gibco) supplemented
with 10% FBS and 100 U/ml penicillin and 100 μg/ml
streptomycin. MCF-10A cells were maintained in
DMEM/F-12 supplemented with 10% FBS, insulin
(10 μg /ml), hydrocortisone (500 ng/ml) and EGF
(20 ng/ml). The cells were collected using 0.05% trypsin
EDTA following the specified incubation period.
Precursor miRNA/siRNA/plasmid transfection
Cells were seeded in 6-well plates at a concentration of
1 × 105 and cultured in medium without antibiotics for
approximately 24 h before transfection. Cells were tran-
siently transfected with miR-203 precursor (Applied Bio-
systems) or negative control miRNA, BIRC5 siRNA
(Sigma), LASP1 siRNA (Sigma) or control siRNA at a
final concentration of 200nM. PcDNA-BIRC5 or
pcDNA-LASP1 plasmid was also transfected into MDA-
MB-231 cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol.
Real-time PCR assay
Total RNA was extracted from cultured cells using the
TRIzol reagent (Invitrogen). cDNA was obtained by re-
verse transcription of total RNA using a TaqMan Re-
verse Transcription Kit (Applied Biosystems) and iScript
cDNA Synthesis kit (BIO-RAD), respectively. The ex-
pression level of mature miR-203 was measured using a
TaqMan miRNA assay (Applied Biosystems) according
to the provided protocol and using U6 small nuclear
RNA as an internal control. Expression of BIRC5 and
LASP1mRNA was detected using Power SYBR Green kit(Applied Biosystems). All experiments were performed
in triplicate.
Colony formation assay
Cells were seeded into a 12-well cell culture plate and
incubated for 2 weeks at 37 °C after treatment. Then,
cells were washed twice with PBS, fixed with cold
methanol, stained with 0.1% crystal violet, washed and
air dried.
Migration assay
Cells were harvested and re-suspended in serum-free
DMEM medium. For the migration assay, 5 × 104 cells
were added into the upper chamber of the insert (BD
Bioscience, 8 μm pore size). Cells were plated in medium
without serum, and medium containing 10% fetal bovine
serum in the lower chamber served as the chemoattract-
ant. After 6 h of incubation, cells were fixed with 3.7%
formaldehyde and stained with crystal violet staining so-
lution, and cells on the upper side of the insert were
removed with a cotton swab. The migratory capacity
was evaluated as the total number of cells on the lower
surface of the membrane, as determined by microscopy.
Western blot analysis
The cells in each well, including dead cells floating in
the medium, were harvested and lysed in RIPA buffer.
The protein concentrations of the lysates were deter-
mined using a bicinchoninic acid protein assay kit
(Pierce Biotech). An aliquot of the lysate containing
50 μg proteins was subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis and then transferred
to polyvinylidene fluoride membranes. The membranes
were blocked with blocking buffer (TBST containing 5%
non-fat milk) for 1 h at room temperature and then
incubated overnight at 4 °C with the following specific
primary antibodies: BIRC5, LASP1 β-actin (Cell Signal-
ing Technology). Subsequent incubation with the appro-
priate horseradish peroxidase-conjugated secondary
antibodies was performed for 2 h at room temperature.
Signals were detected using enhanced chemilumines-
cence reagents (Thermo).
Luciferase reporter assay
To evaluate the function of miR-203, the 3’-UTRs of
BIRC5 and LASP1 with a miR-203 targeting sequence
were cloned into the pMIR-REPORT luciferase reporter
vector (Ambion). The sequences used to amplify BIRC5
3’-UTR were 5’-AAAGCCGGCCTGAAGTCTGGCGTA
AGATG-3’ (forward) and 5’-GGACTAGTCCACATGA
GACTTTATTG-3’ (reverse). The sequences used to
amplify LASP1 3’-UTR were 5’-AAAGCCGGCGTCTT
CTCTACAGTTCAC -3’ (forward) and 5’-GGACTA
GTCCAGGAGAAAGATTCACTTG-3’ (reverse). Mutant
Wang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:58 Page 3 of 8
http://www.jeccr.com/content/31/1/58BIRC5 and LASP1 3’-UTRs bearing a substitution of three
nucleotides (TTT to CCC) in the miR-203 target sequence
were generated using a Site-Directed Mutagenesis Kit
(Agilent Technologies). Cells were co-transfected with
luciferase reporter plasmids and miR-203 precursor (or
control miRNA) along with Renilla Luciferase phRG-TK
(Promega) as an internal control using Lipofectamine
2000 (Invitrogen). Luciferase activity was measured 72 h
after transfection using the Dual-Luciferase Reporter
Assay System (Promega). All experiments were performed
in triplicate.
Statistical analysis
Statistical analysis was performed using one-way
ANOVA or Student’s t test. Values of P< 0.05 were con-
sidered significant. Data were represented as the mean ±
S.D. GraphPad Prism 5.0 software was used for all data
analysis.
Results
miR-203 expression was decreased in TNBC cell lines
while BIRC5 and LASP1 expression was increased
We detected the abundance of miR-203 in triple-
negative human breast cancer cell lines: MDA-MB-468
and MDA-MB-231 and a normal breast cell line: MCF-
10A, by real-time PCR. TNBC cell lines (MDA-MB-468
and MDA-MB-231) showed significant miR-203 repres-
sion than normal breast cell line MCF-10A. We also
detected BIRC5 and LASP1 expression at mRNA level
in breast cancer cell lines and MCF-10A cell line. It was
intriguing that in sharp contrast to the down-regulation
of miR-203 in TNBC cells, BIRC5 and LASP1 expression
is increased in TNBC cell lines compared to that in
MCF-10A (Figure 1B&C). These data may implicate
miR-203 expression is negatively correlated with BIRC5
and LASP1.
miR-203 inhibited proliferation and migration of TNBC
cells
Previous reports have shown that the over-expression of
miR-203 has an impact on growth in prostate and laryn-
geal cancer cell lines [13,14]. Therefore, we investigated
the effect of miR-203 on the proliferation of TNBC cells.
Colony formation assay showed that a statistically sig-
nificant inhibition of TNBC cell proliferation occurred
after treatment with the miR-203 precursor (Figure 2A).
To investigate whether miR-203 inhibits the migration
of TNBC cells, we performed a transwell migration
assay. Interestingly, the over-expression of miR-203
repressed the migration of the MDA-MB-231 and
MDA-MB-468 cells. Cell mobility was significantly
decreased by approximately 50% in miR-203-transfected
cells compared with the control miRNA-transfected cells
(Figure 2B). These observations suggest that miR-203over-expression suppresses the mobility of TNBC cells
in vitro.
miR-203 post-transcriptionally down regulates BIRC5 and
LASP1 expression by targeting the 3’-UTR regions of
BIRC5 and LASP1
To explore the molecular mechanism of miR-203 activ-
ity, we used TargetScan 6.0 to search for target genes
of miR-203, especially for genes with potential roles in
promoting tumor cell proliferation and migration. It
has been reported that individual miRNAs are capable
of regulating dozens of distinct mRNAs. Based on this
rationale, we selected two candidate miR-203 targets,
BIRC5 and LASP1, for further study. We examined the
influence of miR-203 on the endogenous expression of
BIRC5 and LASP1 proteins by western blot. Intri-
guingly, BIRC5 and LASP1 expression were signifi-
cantly decreased in miR-203-transfected MDA-MB-231
and MDA-MB-468 cells compared with control
miRNA-transfected cells (Figure 3A). It was reported
that miRNA can cause either mRNA degradation or
translation repression. QPCR assay was also carried
out to detect BIRC5 and LASP1 expression at mRNA
level after transefected with miR-203 precursor in
TNBC cells. We found that a decrease of BIRC5 and
LASP1 mRNA in TNBC cells after treated (Figure 3B),
so we believe that miRNA-203 regulates BIRC5 and
LASP1 expression at both protein and mRNA levels.
Moreover, a potential miR-203 targeting site was pre-
dicted in the 3’-UTRs of BIRC5 and LASP1 by Tar-
getScan 6.0 (Figure 3C). To investigate whether the 3’-
UTRs of BIRC5 and LASP1 are functional targets of
miR-203 in breast cancer cells, we co-transfected the
miR-203 precursor (or control miRNA) and pMIR-
BIRC5-3’-UTR plasmid (or mutant) or pMIR-LASP1-3’
-UTR plasmid (or mutant) into cells. Co-transfection
with the miR-203 precursor was found to decrease wild
type BIRC5 and LASP1 3’-UTR reporter activity (P<
0.05) compared with co-transfection with control
miRNA in both two cell lines. However, co-
transfection with the miR-203 precursor did not sig-
nificantly alter mutant BIRC5 or LASP1 3’-UTR re-
porter activity (Figure 3D). These results demonstrated
that miR-203 targets the predicted site within the 3’-
UTRs of BIRC5 and LASP1 mRNA in TNBC cell lines.
Repressing BIRC5 expression could inhibit the
proliferation of MDA-MB-231 cells
To investigate the effect of BIRC5 on the proliferation of
TNBC cell, we employed MDA-MB-231 cells as the
model system to perform the subsequent studies. We
evaluated the cell proliferative capacity of MDA-MB-231
cells transfected with BIRC5 siRNA (or control siRNA).
The expression of BIRC5 protein in the cells transfected
Figure 1 miR-203 was down-regulated in TNBC cell lines while BIRC5 and LASP1 expression was up-regulated. (A) Relative miR-203
expression was examined in the indicated breast cancer cell lines and the MCF-10A cell line. (B) Relative BIRC5 expression at mRNA level was
examined in the indicated breast cancer cell lines and the MCF-10A cell line. (C) Relative LASP1 expression at mRNA level was examined in the
indicated breast cancer cell lines and the MCF-10A cell line. miR-203 expression was normalized to that of U6 in each sample. BIRC5 and LASP1
mRNA expression was normalized to that of β-actin in each sample. *, P< 0.05.
Wang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:58 Page 4 of 8
http://www.jeccr.com/content/31/1/58with BIRC5 siRNA was significantly decreased in com-
parison with that of cells transfected with control siRNA
(Figure 4A), indicating that the expression of BIRC5 was
effectively inhibited by BIRC5 siRNA. SubsequentFigure 2 miR-203 inhibited proliferation and migration of TNBC cells.
capacity in MDA-MB-468 and MDA-MB-231 cells treated with control miRN
to detect the migratory capacity of MDA-MB-468 and MDA-MB-231 cells. *,studies showed that the proliferative capacity of cells
transfected with BIRC5 siRNA was significantly lower
than that of cells treated with control siRNA
(Figure 4B).(A) The colony formation assay was used to measure cell proliferation
A or miR-203 precursor. (B) A transwell migration assay was performed
P< 0.05.
Figure 3 BIRC5 and LASP1 were identified as miR-203 target genes. (A) Immunoblots of BIRC5 and LASP1 protein in TNBC cells after treated
with miR-203 precursor or control miRNA. β-actin was used as a loading control. (B) Relative BIRC5 and LASP1 expression at mRNA level in TNBC
cells transfected with miR-203 precursor or control miRNA. The mRNA expression was normalized to that of β-actin. (C) Sequence alignment of
miR-203 and its putative conserved target site in BIRC5 and LASP1 3’-UTR (downloaded from TargetScan 6.0). (D) Luciferase reporter assays of the
interaction between miR-203 and the BIRC5 and LASP1 3’-UTRs. Assays were performed by co-transfection of miR-203 precursor with a luciferase
reporter gene linked to the 3’-UTRs of BIRC5 and LASP1, containing either wild type or mutated miR-203 complementary sites. *, P< 0.05.
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MDA-MB-231 cells
To investigate the effect of LASP1 on the migration of
TNBC cell, we evaluated the cell migratory capacity of
MDA-MB-231 cells transfected with LASP1 siRNA (or
control siRNA). The expression of LASP1 protein in theFigure 4 Repressing BIRC5 expression could inhibit the proliferation
231 cells treated with control siRNA or BIRC5 siRNA. β-actin was used as a
proliferative capacity in MDA-MB-231 cells treated with control siRNA or BIRcells transfected with LASP1 siRNA was significantly
decreased in comparison with that of cells transfected
with control siRNA (Figure 5A), indicating that the ex-
pression of LASP1 was effectively inhibited by LASP1
siRNA. Subsequent studies showed that the migratory
capacity of cells transfected with LASP1 siRNA wasof MDA-MB-231 cells. (A) Immunoblots of BIRC5 protein in MDA-MB-
loading control. (B) Colony formation assay was used to measure cell
C5 siRNA. *, P< 0.05.
Figure 5 Repressing LASP1 expression could inhibit migration of MDA-MB-231 cells. (A) Immunoblots of LASP1 protein in MDA-MB-231
cells treated with control siRNA or LASP1 siRNA. β-actin was used as a loading control. (B) Transwell migration assay was performed to detect the
migratory capacity of MDA-MB-231 cells treated with control siRNA or LASP1 siRNA. *, P< 0.05.
Wang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:58 Page 6 of 8
http://www.jeccr.com/content/31/1/58significantly lower than that of cells treated with control
siRNA (Figure 5B).
The inhibition of MDA-MB-231 cell proliferation by miR-
203 is attenuated by the over-expression of BIRC5
To provide direct evidence that down-regulation of
BIRC5 is required for the anti-tumorigenic effects of
miR-203, we transfected MDA-MB-231 cells with
pcDNA-BIRC5 and miR-203 precursor. We first con-
firmed that BIRC5 and miR-203 have been conducted
into the cells (Figure 6A), then, we used colony forma-
tion assay to show that the inhibition of MDA-MB-231
cell proliferation by miR-203 could be partially rescued
by BIRC5 up-regulated (Figure 6B). These data clearly
indicate that the ectopic over-expression of BIRC5 could
efficiently block the effect on proliferation caused by
miR-203.
The inhibition of MDA-MB-231 cell migration by miR-203
is attenuated by the over-expression of LASP1
To provide direct evidence that miR-203 inhibits the mi-
gration of TNBC cells through the LASP1-mediated signal
pathway, we transfected MDA-MB-231 cells with miR-
203 precursor and pcDNA-LASP1. We confirmed the ef-
fect of the transfection by western blot (Figure 7A). TheFigure 6 Over-expression of BIRC5 could significantly attenuate the e
proliferation. (A) BIRC5 protein expression was detected by western blot a
was performed to detect proliferative capacity in MDA-MB-231 cells. *, P<migration assay showed that the over-expression of
LASP1 could partially rescue the migratory capacity of
MDA-MB-231 cells treated with the miR-203 precursor
(Figure 7B).
Discussion
The recent discovery of a class of small non-coding RNAs,
called microRNAs, has received significant attention in
cancer research [15,16]. The aberrant expression of onco-
genic miRNAs is associated with the development and
progression of many cancers, including breast cancer.
Conversely, the over-expression of tumor suppressor miR-
NAs may repress cancer cell proliferation and migration,
but the mechanisms by which miRNAs affect oncogenesis
remain to be elucidated. In the present study, we showed
that miR-203 is down-regulated in TNBC cell lines com-
pared with the normal breast cell line. Moreover, we
showed that the over-expression of miR-203 could sup-
press the proliferation and migration of TNBC cells, ac-
companied by a decrease in the expression of BIRC5 and
LASP1, suggesting that miR-203 has tumor-suppressive
effects in TNBC.
Consistent with our results, miR-203 expression is
down regulated in several cancer cells, including liver
cancer [11], prostate cancer [13], and some types offfect of miR-203 on the inhibition of MDA-MB-231 cell
nd normalized to β-actin protein levels. (B) Colony formation assay
0.05.
Figure 7 Over-expression of LASP1 significantly attenuated the effect of miR-203 on the inhibition of MDA-MB-231 cell migration. (A)
LASP1 protein expression was detected by western blot and normalized to the levels of β-actin protein. (B) Transwell migration assay was
performed to detect the migratory capacity of MDA-MB-231 cells. *, P< 0.05.
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pression in esophageal cancer cell lines repressed
ΔNP63 levels, inhibited cell growth and promoted apop-
tosis [17]. Taken together, these results suggest that
miR-203 may act as a tumor suppressor and is down-
regulated in cancer development. It has also reported
that individual miRNAs are capable of regulating dozens
of distinct mRNAs, so we considered the possibility that
miRNA-203 might act on several target genes rather
than a single target. We identified two potential miR-
203 target genes: BIRC5 and LASP1.
BIRC5 is expressed during embryonic and fetal devel-
opment but is undetectable in terminally differentiated
normal adult tissue. However, it is re-expressed in
human cancer cells at a frequency of 34-100% [18,19].
BIRC5 is a member of the IAP family of proteins that
contain a single BIR domain and an extended C-
terminal helical coiled-coil domain [20,21]. Up-
regulation of BIRC5 is a frequent event in breast cancer,
suggesting that BIRC5 may play an important role in
tumorigenesis; furthermore, its expression in breast can-
cer tissue is significantly associated with poor clinical
outcome [22-25]. It was reported that BIRC5 knockdown
might inhibit proliferation and induce apoptosis in can-
cer cells [26]. Here, we used MDA-MB-231 as a TNBC
cell model to demonstrate that repressing BIRC5 expres-
sion by siRNA could significantly inhibit the prolifera-
tion of TNBC cell lines, implying that BIRC5 played a
positive role in TNBC cell proliferation. Moreover, we
showed that BIRC5 over-expression could partially abro-
gate the proliferate inhibition induced by miR-203. This
key observation indicates that the negative control of
BIRC5 levels is a critical aspect of the tumor-suppressive
activity of miR-203 in TNBC. Therefore, the identifica-
tion of BIRC5 as a miR-203 target gene may explain, at
least in part, the molecular mechanism of tumor sup-
pression by miR-203.LASP1 was initially identified in a cDNA library pre-
pared from breast cancer metastases. The LASP1 protein
includes three domains: an N-terminal LIM domain, a
nebulin repeat domain and a C-terminal SH3 domain
[27]. LASP1 is expressed at low basal levels in all normal
human tissues, but is over-expressed in metastatic
human breast cancer [28], ovarian cancer [29] and
medulloblastoma [30]. Increased LASP1 expression
could lead to a more aggressive breast carcinoma pheno-
type, and knocking down LASP1 may reduce the migra-
tory capacity of breast cancer cells, possibly by
influencing the localization of zyxin [29]. In our study,
we identified the LASP1 transcript as a target of miR-
203 in TNBC cells and found that inhibition of TNBC
cell migratory capacity was accompanied by a reduction
in LASP1 expression. We also showed that repressing
LASP1 expression by siRNA could significantly inhibit
the migration of MDA-MB-231 cells, implying that
LASP1 played a positive role in TNBC cell migration.
Moreover, we demonstrated that decreased LASP1 ex-
pression is essential for the miR-203-mediated inhibition
of TNBC cell migration, showing that the over-
expression of LASP1 could partially rescue the migration
inhibition induced by miR-203 in MDA-MB-231 cells.
In conclusion, our data suggest that miR-203 could in-
hibit the proliferation and migration of TNBC cells by
directly regulating the expression of BIRC5 and LASP1.
Moreover, the activation of miR-203 may be a potentially
useful novel strategy for inhibiting TNBC growth and
metastasis.
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